Cartesian Therapeutics, Inc.’s RNAC share price has surged by 8.40%, which has investors questioning if this is right time to sell.

Shares of Cartesian Therapeutics climbed after the company announced positive results in a phase 2b trial of its lead cell-therapy candidate. The stock was up 8.3% to $15.60 in morning trading Tuesday ...

Cartesian Therapeutics, Inc.’s RNAC share price has dipped by 18.96%, which has investors questioning if this is right time ...

The insurance industry can be seemingly opaque, and Jason enjoys breaking down confusing terms and products to help others mak... Les Masterson is a deputy editor and insurance analyst at Forbes ...

“Normally, I am repulsed by the idea of food-related scents applied to areas prone to body odor, but this vanilla deodorant has won me over. Sometimes I’ll catch a sniff of something truly ...

Opinions expressed are those of the author. Product marketing continues to emerge as a critical function in many organizations, gaining a reputation distinct from traditional marketing in growing ...

Descartes-08, Cartesian’s lead product candidate, is an autologous anti-B cell maturation antigen (BCMA) mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T). In January 2025 ...

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in Descartes-08-treated participants in Phase 2b trial ...